Zhonghong Pulin Medical Products Co. Ltd. - Asset Resilience Ratio
Zhonghong Pulin Medical Products Co. Ltd. (300981) has an Asset Resilience Ratio of 34.68% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Zhonghong Pulin Medical Products Co. Ltd (300981) working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Zhonghong Pulin Medical Products Co. Ltd.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 300981 total asset value.
Liquid Assets Composition Over Time
This chart breaks down Zhonghong Pulin Medical Products Co. Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Zhonghong Pulin Medical Products Co. Ltd (300981) financial obligations for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥2.67 Billion | 34.68% |
| Total Liquid Assets | CN¥2.67 Billion | 34.68% |
Asset Resilience Insights
- Very High Liquidity: Zhonghong Pulin Medical Products Co. Ltd. maintains exceptional liquid asset reserves at 34.68% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Zhonghong Pulin Medical Products Co. Ltd. Industry Peers by Asset Resilience Ratio
Compare Zhonghong Pulin Medical Products Co. Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ansell Ltd
AU:ANN |
Medical Instruments & Supplies | 7.53% |
|
Eyebright Medical Technology Beijing Co Ltd
SHG:688050 |
Medical Instruments & Supplies | 1.51% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 18.11% |
|
Vizionfocus Inc.
TW:4771 |
Medical Instruments & Supplies | 3.24% |
|
Pro-Dex Inc
NASDAQ:PDEX |
Medical Instruments & Supplies | 1.39% |
|
Nyxoah
BR:NYXH |
Medical Instruments & Supplies | 12.40% |
|
Mark Dynamics Indonesia Tbk PT
JK:MARK |
Medical Instruments & Supplies | 6.64% |
|
Interojo Inc
KQ:119610 |
Medical Instruments & Supplies | 6.55% |
Annual Asset Resilience Ratio for Zhonghong Pulin Medical Products Co. Ltd. (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Zhonghong Pulin Medical Products Co. Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 25.29% | CN¥1.88 Billion ≈ $275.30 Million |
CN¥7.44 Billion ≈ $1.09 Billion |
+1.40pp |
| 2024-12-31 | 23.89% | CN¥1.73 Billion ≈ $252.78 Million |
CN¥7.23 Billion ≈ $1.06 Billion |
-8.13pp |
| 2023-12-31 | 32.03% | CN¥2.26 Billion ≈ $330.71 Million |
CN¥7.06 Billion ≈ $1.03 Billion |
-5.27pp |
| 2022-12-31 | 37.29% | CN¥2.54 Billion ≈ $371.99 Million |
CN¥6.82 Billion ≈ $997.49 Million |
-12.55pp |
| 2021-12-31 | 49.84% | CN¥3.56 Billion ≈ $521.62 Million |
CN¥7.15 Billion ≈ $1.05 Billion |
+39.43pp |
| 2020-12-31 | 10.41% | CN¥382.43 Million ≈ $55.96 Million |
CN¥3.67 Billion ≈ $537.43 Million |
-- |
About Zhonghong Pulin Medical Products Co. Ltd.
Zhonghong Pulin Medical Products Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of disposable health protection products, sterile medical devices, and life support solutions in China and internationally. It operates through the Health Protection Products Division; Safe Infusion Products Division; and Innovation and Incubation Product Division… Read more